Recordati sizes up €10.9bn CVC Capital acquisition offer

Italian pharmaceutical company, Recordati, has confirmed that it’s weighing an acquisition connection from backstage equity manager, CVC, which is looking to solidify its controlling involvement successful the company.

If Recordati greenlights this deal, CVC would wage €52 ($60) per stock for the remaining 48.2% of the erstwhile company’s shares disposable connected the Italian Stock Exchange – perchance mounting CVC backmost by €10.9bn ($12.6bn).

While Recordati noted it has “not yet reviewed the denotation of involvement wrong its firm bodies” for this deal, the institution already has beardown ties with CVC, arsenic the steadfast antecedently acquired a controlling involvement successful Recordati by buying 51.8% of its banal for €3.03bn successful 2018.

Recordati, which celebrates its 100th day this year, is simply a planetary pharmaceutical radical focused connected superior and secondary care, arsenic good arsenic uncommon diseases wrong the areas of haematological oncology, endocrinology and metabolic health.

The pharma institution has respective portfolio products connected the market, including its best-selling Cushing’s illness therapy, Isturisa (osilodrostat), for which an expert statement estimation by GlobalData projects income of $967m successful 2031.

Recordati besides precocious added the acold agglutinin illness (CAD) medicine, Enjaymo (sutimlimab), to its attraction arsenal. The Italian pharma acquired the planetary rights to this cause from Sanofi for $825m upfront successful 2024.

Meanwhile, the institution has besides partnered with mRNA specializer Moderna to make a propionic acidaemia therapy, mRNA-3927, which is presently successful planetary Phase I/II trials.

Recordati’s financials are looking positive, arsenic the company’s nett gross climbed 11.8% to €2.6bn successful 2025. The beardown show of the company's uncommon illness drugs chiefly drove its maturation successful 2025, with revenues successful this country ballooning by 29.7% compared with 2024.

CVC’s projected takeover bid comes amid a flurry of pharma M&A deals announced implicit the past week, arsenic large players successful the assemblage look to fortify their pipelines successful mentation for the looming patent expiries soon to deed their portfolios.

Today (27 March), Novartis announced it volition beryllium acquiring Excellergy for up to $3bn, frankincense absorbing the company’s half-life extended, high-affinity anti-IgE antibody called EXL-111, which is presently successful Phase I objective trials.

Earlier this week, MSD (Merck & Co) handed implicit $6.7bn to bargain Terns Pharmaceuticals – a woody valuation that immoderate analysts judge does not afloat seizure the imaginable of TERN-701, its BCR-ABL1 tyrosine kinase inhibitor (TKI).

On 24 March, Gilead made its archetypal moves successful the T-cell engager (TCE) marketplace with its $2.2bn acquisition of Ouro Medicines, which could spot the institution squad up with Galapagos to make Ouro’s pb asset, gamgertamig.